{"filing":{"accession_number":"0001193125-26-385886","cik":"0001863127","ticker":"TYRA","company_name":"Tyra Biosciences, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"d167841d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526385886/d167841d8k.htm"},"events":[{"id":32175,"run_id":29557,"accession_number":"0001193125-26-385886","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Tyra announced initial Phase 2 clinical trial results for dabogratinib in FGFR3-altered bladder cancer (SURF302), demonstrating favorable safety and efficacy outcomes (79% ORR at 60 mg QD, no Grade 4/5 adverse events) and identifying the dose for planned Phase 3 registrational studies. This is a material clinical development milestone for a biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results disclosures) nor any other specific taxonomy type.","company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35286,"accession_number":"0001193125-26-385886","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Tyra announced initial Phase 2 clinical trial results for dabogratinib in FGFR3-altered bladder cancer (SURF302), demonstrating favorable safety and efficacy outcomes (79% ORR at 60 mg QD, no Grade 4/5 adverse events) and identifying the dose for planned Phase 3 registrational studies. This is a material clinical development milestone for a biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results disclosures) nor any other specific taxonomy type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:10:57.410276+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35286,"accession_number":"0001193125-26-385886","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Tyra announced initial Phase 2 clinical trial results for dabogratinib in FGFR3-altered bladder cancer (SURF302), demonstrating favorable safety and efficacy outcomes (79% ORR at 60 mg QD, no Grade 4/5 adverse events) and identifying the dose for planned Phase 3 registrational studies. This is a material clinical development milestone for a biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results disclosures) nor any other specific taxonomy type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:10:57.410276+00:00","company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","filing_date":"2026-09-09"}]}